Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INA03 in Relapsed/Refractory Acute Leukemia
NCT03957915Phase 1Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- May 2020
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INA03 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL), sponsored by Institut Paoli-Calmettes. Primary endpoints: Minimal Erythroblastopenia-Inducing Dose at 2 weeks and Maximum Tolerated Dose at 28 days. Started May 2020; status: completed.
02
Drugs
INA03
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT03957915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957915.